Sight Sciences, a California-based eyecare technology company focusing on creating innovative solutions to transform care and improve patients’ lives, has announced the appointment of Ali Bauerlein as its new Chief Financial Officer and Treasurer, effective from April 3, 2023.
This appointment follows the exceptional growth and success of Sight Sciences as a company, with the aim of driving further scalable growth while securing the financial infrastructure necessary to support the growth of the company. Bauerlein, renowned for her skills and experience, joins Sight Sciences from Inogen, a medical technology company, where she served as Chief Financial Officer from 2009 through 2021.
Paul Badawi, co-founder and CEO of Sight Sciences, was pleased with the appointment, noting that Bauerlein’s experience in leading a rapidly growing medtech organization through multiple phases of growth, would provide an immediate and valuable impact.
Sight Sciences’ focus on creating innovative solutions to transform care and improve patients’ lives has seen the company develop a portfolio and pipeline of products that disrupt two multibillion-dollar markets, generating top-tier revenue growth. Bauerlein’s experience with high growth medtech will play an essential role in Sight Sciences achieving its fullest potential.
Bauerlein oversaw the global finance and accounting function at Inogen, including financial planning, treasury functions, SEC reporting, investor relations, business development, and tax, as it scaled from start-up operations to over $350 million in annual sales.
The appointment of Bauerlein as Chief Financial Officer and Treasurer at Sight Sciences comes at a time when the company is experiencing a notable surge in growth as it continues to develop cutting-edge solutions in ophthalmic care. Bauerlein’s experience in financial management, coupled with her extensive knowledge of the healthcare and medtech sector, is set to play an integral role in driving Sight Science’s future growth trajectory.
Bauerlein noted her excitement at joining Sight Sciences, a company that leads eyecare technology innovation with an AIM to improve patients’ lives while creating more effective treatment paradigms. She expressed her delight at partnering with the Sight Sciences team and working with Badawi to support their current growth and profitability plans, while striving to create maximum value for the ophthalmic community and stockholders.
Sight Sciences’ OMNI® Surgical System, a minimally invasive glaucoma surgery (MIGS) device used to reduce intraocular pressure in adult patients with primary open-angle glaucoma (POAG), is a product whose efficacy and efficiency are set to disrupt the industry.
The SION™ Surgical Instrument, a bladeless, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork, is another revolutionary product from Sight Sciences poised to transform ophthalmic care. Additionally, the TearCare® System, 510(k) cleared in the United States, applies localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD), making it possible for physicians to address the leading cause of dry eye disease through office-based clearance of gland obstructions.
Sight Sciences continues to inspire innovation and set new standards in the ophthalmic industry through its cutting-edge solutions that focus on improving patients’ lives. The appointment of Bauerlein is a significant boost to the company, as it continues to drive innovation and steady growth while providing invaluable contributions to healthcare.
In Other News Around the World: